The Former Yugoslav Republic of MacedoniaTuberculosis profile
Population  2015 2.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.41 (0.37–0.44)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0 (0–0.01)
Incidence  (includes HIV+TB) 0.27 (0.26–0.28) 13 (12–14)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0.03–0.04)
Incidence (MDR/RR-TB)** <0.01 (<0.01–0.016) 0.44 (0.12–0.77)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.011 (<0.01–0.015) 0.093 (0.073–0.11) 0.1 (0.08–0.13)
Males 0.011 (<0.01–0.014) 0.16 (0.12–0.19) 0.17 (0.13–0.2)
Total 0.022 (0.017–0.026) 0.25 (0.24–0.26) 0.27 (0.26–0.28)
TB case notifications, 2015  
Total cases notified 284
Total new and relapse 282
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 66%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 100% (100–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.03 (0.03–0.04)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0 0%
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  6
(1–12)
Estimated % of TB cases with MDR/RR-TB 2.4% (0.65–6) 6.7% (0.17–32)  
% notified tested for rifampicin resistance 64% 65% 183
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 5, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 5, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 87% 281
Previously treated cases, excluding relapse, registered in 2014 100% 1
HIV-positive TB cases, all types, registered in 2014 0% 1
MDR/RR-TB cases started on second-line treatment in 2013 50% 2
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 2.1
Funding source: 6% domestic, 94% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-10-18 Data: www.who.int/tb/data